Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
471 12 |
Ultima descărcare din IBN: 2024-04-21 18:14 |
Căutarea după subiecte similare conform CZU |
616-006.448-08(478) (1) |
Patologie. Medicină clinică (6964) |
SM ISO690:2012 ROBU, Maria, FOSA, Olga, BURUIANA, Sanda, POPESCU, Maria, TOMACINSCHII, Victor, GOLUB, Aliona, FEGHIU, Veronica. Tratamentul mielomului multiplu în Republica Moldova.. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2020, nr. 4(68), pp. 288-292. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 4(68) / 2020 / ISSN 1857-0011 | ||||||
|
||||||
CZU: 616-006.448-08(478) | ||||||
Pag. 288-292 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Au fost studiate aspectele clinice și rezultatele tratamentului la 151 pacienți cu mielom multiplu în vârstă de la 32 pînă la 86 de ani. S-a constatat că mielomul multiplu s-a dezvoltat mai frecvent la persoanele cu vârstă de 60-69 ani (48,3%) și a predominat la femei (57,6%). Majoritatea pacienților (96,0%) au fost diagnosticați în stadiile avansate (II și III) ale maladiei, preponderent stadiul III (57,6%). Insuficiența renală a fost prezentă la jumătate din pacienți (49,7%). Eficacitatea tratamentului atît de prima linie, cît și de a doua linie în cazurile de avansare a mielomului multiplu a fost mai înaltă la pacienții la care s-a aplicat PChT cu includerea de bortezomib (inhibitor de proteazomi) (76,0% și 88,1%, respectiv). Perioada stabilizării procesului tumoral a fost mai mare tot la bolnavii la care s-au administrat schemele cu bortezomib. Metoda optimală de tratament din cele utilizate la pacienții cu mielom multiplu a fost PChT conform schemei BTD (bortezomib, talidomidă, dexametazonă). |
||||||
Cuvinte-cheie mielom multiplu, Tratament, inhibitori de proteazomi, multiple myeloma, treatment, proteosomal inhibitors |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-132443</cfResPublId> <cfResPublDate>2020-12-30</cfResPublDate> <cfVol>68</cfVol> <cfIssue>4</cfIssue> <cfStartPage>288</cfStartPage> <cfISSN>1857-0011</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/132443</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Tratamentul mielomului multiplu în Republica Moldova.</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>mielom multiplu; Tratament; inhibitori de proteazomi; multiple myeloma; treatment; proteosomal inhibitors</cfKeyw> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Au fost studiate aspectele clinice și rezultatele tratamentului la 151 pacienți cu mielom multiplu în vârstă de la 32 pînă la 86 de ani. S-a constatat că mielomul multiplu s-a dezvoltat mai frecvent la persoanele cu vârstă de 60-69 ani (48,3%) și a predominat la femei (57,6%). Majoritatea pacienților (96,0%) au fost diagnosticați în stadiile avansate (II și III) ale maladiei, preponderent stadiul III (57,6%). Insuficiența renală a fost prezentă la jumătate din pacienți (49,7%). Eficacitatea tratamentului atît de prima linie, cît și de a doua linie în cazurile de avansare a mielomului multiplu a fost mai înaltă la pacienții la care s-a aplicat PChT cu includerea de bortezomib (inhibitor de proteazomi) (76,0% și 88,1%, respectiv). Perioada stabilizării procesului tumoral a fost mai mare tot la bolnavii la care s-au administrat schemele cu bortezomib. Metoda optimală de tratament din cele utilizate la pacienții cu mielom multiplu a fost PChT conform schemei BTD (bortezomib, talidomidă, dexametazonă).</p></cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'><p>In this trial were studied clinical aspects and treatment outcomes of 151 patients with multiple myeloma aged 32 to 86 years. It was found that multiple myeloma developed more frequently in people aged 60-69 years (48.3%) and predominated in women (57.6%). Most patients (96.0%) were diagnosed in the advanced stages (II and III) of the disease, mainly in III stage (57.6%). Renal failure was present in half of the patients (49.7%). The efficacy of both first-line and second-line treatment in cases of multiple myeloma progression was higher in patients treated with PChT including bortezomib (proteosomal inhibitor) (76.0% and 88.1%, respectively). The period of stabilization of the tumor process was also longer in patients receiving bortezomib regimens. The optimal treatment method used in patients with multiple myeloma was PChT according to the BTD regimen (bortezomib, thalidomide, dexamethasone).</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11551</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-60806</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-17453</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29191</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-60743</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-60807</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-60805</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11551</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11551-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Robu</cfFamilyNames> <cfFirstNames>Maria</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-60806</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-60806-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Fosa</cfFamilyNames> <cfFirstNames>Olga</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-17453</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-17453-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Buruiana</cfFamilyNames> <cfFirstNames>Sanda</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29191</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29191-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Popescu</cfFamilyNames> <cfFirstNames>Maria</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-60743</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-60743-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Tomacinschii</cfFamilyNames> <cfFirstNames>Victor</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-60807</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-60807-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Golub</cfFamilyNames> <cfFirstNames>Aliona</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-60805</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-60805-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-12-30T24:00:00</cfStartDate> <cfFamilyNames>Feghiu</cfFamilyNames> <cfFirstNames>Veronica</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>